

## Images in Infectious Diseases

# Alveolar echinococcosis mimicking bilateral lung metastatic cancer

Yener Aydin<sup>[1]</sup> , Ali Bilal Ulas<sup>[1]</sup>  and Atilla Eroglu<sup>[1]</sup> 

[1]. Ataturk University, Medical Faculty, Department of Thoracic Surgery, Erzurum, Turkey.

A 62-year-old male presented with dyspnea, cough, and severe chest pain complaints. The patient was diagnosed with hepatic alveolar echinococcosis 13 years ago. Widespread metastasis was seen in the posteroanterior chest radiograph of the patient, who was treated with albendazole (**Figure 1**).

The incidence of alveolar echinococcosis caused by the larval forms of the *Echinococcus multilocularis* has increased in recent years. Lung metastases occur in 7-20% of patients with liver involvement<sup>1,2</sup>. Alveolar echinococcosis behaves like a tumor. Treatment with albendazole may slow the growth of metastases<sup>1</sup> in patients with diffuse metastatic nodules in the lung, and alveolar echinococcosis should be considered as a cause.

### REFERENCES

1. Aydin Y, Ogul H, Topdagi O, Ulas AB, Sade R, Ozturk G, et al. Relevance of Pulmonary Alveolar Echinococcosis. Arch Bronconeumol (Engl Ed). 2020;56(12):779-83.
2. Aydin Y, Altuntaş B, Eroğlu A, Oğul H, Aydın B. Treatment approach for pulmonary alveolar echinococcosis. Türk Göğüs Kalp Dama. 2017;25(2):223-9.



**FIGURE 1:** Chest radiograph shows multiple metastatic nodules in all lobes of both lungs.

**Corresponding author:** Dr. Yener Aydin. **e-mail:** dryeneraydin@hotmail.com

**Authors' contribution:** YA: Conception and design of the study, Acquisition of data, Drafting the article, Final approval of the version to be submitted; ABU: Conception and design of the study, Analysis and interpretation of data; AE: Conception and design of the study, Analysis and interpretation of data.

**Conflict of Interest:** The authors declare that there is no conflict of interest.

**Financial Support:** The authors declare that the article content was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

**Received** 16 March 2022 | **Accepted** 24 May 2022